DTM collects and manufactures the majority of blood components transfused in the Clinical Center. In addition, DTM collects, processes, and stores a wide range of cellular therapy products under IND for Phase I/II clinical trials. DTM has three clinical laboratories that manage blood donor testing and patient diagnostic testing: the Transfusion Service and Immunohematology Reference Laboratory, the HLA Laboratory, and the Transfusion Transmitted Viruses Laboratory. It also has the CCE.
The purpose of this position is to serve as the Chief of the Cell Therapy Manufacturing Section which is a dynamic and expanding organization that operates more than one facility that operates twenty-four hour services.
If selected for this position, duties will include:
Setting Section goals, objectives and priorities to achieve and further the strategic direction for the CCE and developing plans to implement these;
Ensuring that Section activities are consistent with current standards of practice and regulations;
Evaluating staff and organizational effectiveness in accomplishing assigned goals and tasks, and trouble-shooting problems that arise in accomplishing the goals and objectives of the CCE and the Section;
Ensuring that the cell processing goals of intramural clinical investigators are met;
Developing and implementing more efficient and streamlined Section methods and procedures for the Section to accomplish the goals and objectives of the CCE;
Overseeing Section quality improvement related activities to promote safe and efficient Section services;
Establishing Section priorities, analyzing issues and making decisions based on supportable data and judgement;
Developing, and implementing budget strategies to support the CCE expectations; and developing, implementing and evaluating cost saving initiatives;
Managing resources allocated to the Section including identifying and justifying needs for additional resources or redeploying resources in new ways to meet the needs of the Section and the initiatives of the CCE;
Develop and maintain measure of CTM activity;
Supporting the development and maintenance of information technology systems;
Supporting the transfer of new cell therapies from the NPM section to CTM;
Reviewing and approving plans developed by subordinate supervisors for workforce supervision and development to assure the availability of an engaged, highly specialized and high performing staff;
Developing, evaluating, and adjusting organizational structures and management systems for the cell engineering products and services managed;
Ensuring that subordinate supervisors are properly trained and execute their human resource management responsibilities in accordance with NIH, HHS, EEOC and OPM policies and regulations.
Conditions of Employment
U.S. Citizenship requirement or proof of being a U.S. National must be met by closing date.
Employment is subject to the successful completion of the pre-appointment process (i.e., background investigation, verification of qualifications and job requirements, completion of onboarding forms, submission of required documents, etc.)
A Pre-Employment Physical is required for this position.
Males born after December 31, 1959 must be registered with the Selective Service.
Applicants must meet all qualifications requirements within thirty (30) calendar days of the closing date of this announcement.
Position requires Education.
Position is designated as Emergency Essential.
Basic Qualifications: Successful completion of a full 4-year course of study in an accredited college or university, leading to a bachelor's or higher degree, with major study in an academic field related to the medical field, health sciences or allied sciences appropriate to the work of the position.
Additional Qualification Requirements: You must demonstrate in your resume at least one (1) year of qualifying experience equivalent to at least the GS-13 level in the Federal Government. performing the following types of tasks: managing the technical and administrative operations of a laboratory engaged in manufacturing cell and/or gene therapies; developing policy guidance and procedural materials for laboratory personnel; overseeing a quality assurance program to ensure safety and optimal laboratory services as they relate to the manufacturing of cell and/or gene therapies; performing administrative work in areas such as budget and financial management, procurement and contracting, personnel management, space, safety and inventory control; and serving as a technical authority providing advice and guidance to clinicians and researchers regarding cell and/or gene therapy manufacturing.
Do not copy and paste the duties, specialized experience, or occupational assessment questionnaire from this announcement into your resume as that will not be considered a demonstration of your qualifications for this position.
Experience refers to paid and unpaid experience, including volunteer work done through National Service programs (e.g., Peace Corps, AmeriCorps) and other organizations (e.g., professional; philanthropic; religious; spiritual; community; social). Volunteer work helps build critical competencies, knowledge, and skills and can provide valuable training and experience that translates directly to paid employment. You will receive credit for all qualifying experience, including volunteer experience.
Internal Number: NIH-CC-MP-20-10632347
About National Institute of Health, Clinical Center
At the NIH Clinical Center, clinical research participants—more than 500,000 since the hospital opened in 1953—are active partners in medical discovery, a partnership that has resulted in a long list of medical milestones, including development of chemotherapy for cancer; the first use of an immunotoxin to treat a malignancy (hairy cell leukemia); identification of the genes that cause kidney cancer, leading to the development of six new, targeted treatments for advanced kidney cancer; the demonstration that lithium helps depression; the first gene therapy; the first treatment of AIDS (with AZT); and the development of tests to detect AIDS/HIV and hepatitis viruses in blood, which led to a safer blood supply. Patients come from all 50 states and from around the world.